medigraphic.com
ISSN 0188-9796 (Print)

2010, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2010; 18 (3)

Evaluation of biochemical and clinical hypogonadism in adult males with type 2 diabetes

Isibasi-Carrillo LF, Rivera-López E, Vergara-López A, Guillén-González MA

Language: Spanish
References: 22
Page: 141-145
PDF size: 260.05 Kb.


ABSTRACT

Background: Erectile dysfunction and gonadal abnormalities are common in patients with diabetes. How frequent this problem is in Mexican patients with diabetes is largely unknown. Objective: To report the clinical and biochemical androgen status of patients with type 2 diabetes mellitus at CMN 20 de Noviembre. Patients and methods: We studied all male patients diagnosed with type 2 diabetes mellitus, aged 30 to 75 years, attending our outpatient clinic from May to July 2009. Serum levels of total testosterone (TT), FSH and LH were measured. BMI, metabolic control and comorbidities were recorded. The ADAM questionnaire was applied to document symptoms of hypogonadism. Definitive hypogonadism was defined as the presence of TT levels &#no amor8249 8 nmol/L associated with a positive ADAM questionnaire and probable hypogonadism as TT levels were between 8 and 12 nmol/L associated with a positive questionnaire ADAM. Results: Six men (17.64%) had definitive hypogonadism whereas 4 men (11.8%) had probable hypogonadism with TT levels between 8 and 12 nmol/L. Six of these 10 patients had low gonadotrophin levels. Therefore 29.4% had TT levels below 12 nmol/L, associated with symptoms. No association was found between T levels and BMI or HbA1c. Conclusions: Hypogonadism is common in patients with type 2 diabetes.


REFERENCES

  1. Dwyer AA, Hayes FJ, Plummer L, Pitteloud N, Crowley WF. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 2010; 95: 4235-4243.

  2. Nachtigall LB, Boepple PA, Pralong FP, Crowley WF. Adult-onset idiopathic hypogonadotrophic hypogonadism – A treatable form of male infertility. N Engl J Med 1997; 336: 410-415.

  3. Mohr BA, Guay AT, O´Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Aging Study. Clin Endocrinol 2005; 62: 64-73.

  4. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middleaged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589-598.

  5. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdoloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.

  6. Wu FCW, Tajar A, Pye SR, Sillman AJ, Finn JD, O´Neil TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi F, Kula K, Punab M, Boonen S, Vandrschueren D. The European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The EMAS. J Clin Endocrinol Metab 2008; 93: 2737-2745.

  7. Wu FCW, Tajar A, Beynon JM, Pye SR, Phil M, Silman PA, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Ginercman A, Han TS, Kula K, Lean MEJ, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 16: 1-13.

  8. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807-811.

  9. Defay R, Papoz L, Barny S, Bonnot-Lours S, Caces E, Simon D. Hormonal status an NIDDDM in the European and Melanesian population of New Caledonia: a case-control study. The CALedonia DIAbetes Mellitus (CALDIA) Study Group. Int J Obes Relat Metab Disord 1998; 22: 927-934.

  10. Laaksonen DE, NIskanen L, Punnonen K, Nyyssönen F, Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middleaged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90: 712-719.

  11. Grossman M, Thomas M, Pangiotopoulos S, Sharpe K, Macisaac S, Clarke S, Zajac J, Jerums G. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93: 1834-1840.

  12. Dhindsa S, Prabhakar S, Sehi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462-5468.

  13. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636-2641.

  14. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731.

  15. Andersson B, Marin P, Lissner L, Vemeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405-411.

  16. Tripathy D, Dhindsa S, Garg R, Khaishagi A, Syed T, Dandona P. Hypogonadotrophic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect? Metabol Syndr Relat Disord 2003; 1: 75-81.

  17. Ando S, Rubens R, Rottiers R. Androgen plasma levels in male diabetics. J Endocrinol Invest 1984; 7: 21-24.

  18. Travison T, Araujo AB, Kupelian V, O´Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92: 549-555.

  19. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol 2005; 63: 239-250.

  20. Watanobe H, Hayakawa Y. Hypothalamic interleukin-1 and tumor necrosis factor-, but no interleukin-7, mediate the endotoxin-induce suppression of the reproductive axis in rats. Endocrinology 2003; 144: 4868-4875.

  21. Russell SH, Samll CJ, Stanley SA, Franks S, Ghatei MA, Bloom SR. The in vitro role of tumour necrosis factor- an interleukin-6 in the hypothalamic pituitary gonadal axis. J Neuroendocrinol 2001; 13: 296-301.

  22. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnooff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.




2020     |     www.medigraphic.com